| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| 10g |
|
||
| Other Sizes |
| Targets |
6-Benzyloxyindole serves as an antiviral and antitumor agent. The indole scaffold is a common motif in numerous biologically active compounds with diverse pharmacological activities. The compound does not have a well-defined single target but is studied for its potential antiviral and antitumor properties.
|
|---|---|
| ln Vitro |
In vitro, 6-benzyloxyindole is primarily used as a chemical reagent and synthetic intermediate. It is described as an indole derivative with antiviral and antitumor activity. As a benzyl-protected hydroxyindole, it is a building block for the synthesis of more complex indole-based compounds in medicinal chemistry.
|
| ln Vivo |
In vivo data for 6-benzyloxyindole as a therapeutic agent are limited. The compound's antiviral and antitumor activities have been suggested, but specific in vivo efficacy and pharmacokinetic data are not well-documented. Its in vivo relevance is primarily indirect, through the biological activities of the final compounds derived from its indole scaffold.
|
| Enzyme Assay |
For in vitro antiviral assays, 6-benzyloxyindole can be evaluated against various viruses. Standard protocols involve infecting cells with virus and treating with the compound at various concentrations (typically 0.1-100 µM) for 24-72 hours. Viral replication is measured by plaque reduction assay or by quantifying viral nucleic acids. Cytotoxicity is assessed in parallel using MTT assays. For antitumor activity, cancer cell lines are treated with the compound and cell viability is assessed.
|
| Cell Assay |
For in vitro cell-based experiments, 6-benzyloxyindole is used as an intermediate in the synthesis of compounds that are tested in cell viability, proliferation, and cytotoxicity assays. The compound itself may be evaluated for its own antiviral and antitumor activities. Standard cell culture protocols involve dissolving the compound in DMSO and diluting to working concentrations.
|
| Animal Protocol |
In vivo animal studies using 6-benzyloxyindole are conducted on the final drug compounds synthesized from it, not on the intermediate itself. For antiviral and antitumor candidates derived from this building block, efficacy studies would typically be performed in mouse models of viral infection or cancer. Standard in vivo protocols involve administration to rodents via oral gavage or intraperitoneal injection.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6-benzyloxyindole as a standalone compound are not characterized in the literature. The compound has a molecular weight of 223.27 g/mol, which is within the favorable range for oral bioavailability. The benzyl ether may be cleaved in vivo to release the phenolic indole. Empirical pharmacokinetic data are not available.
|
| Toxicity/Toxicokinetics |
6-Benzyloxyindole is a research chemical and should be handled with appropriate laboratory safety precautions. As an indole derivative, it may cause skin and eye irritation. The compound is for research use only and not for human therapeutic or diagnostic applications. Specific LD₅₀ values and acute toxicity classifications are not available.
|
| Additional Infomation |
6-Benzyloxyindole (6-(Benzyloxy)-1H-indole, CAS 15903-94-3) is primarily a research-grade chemical intermediate and biochemical reagent, not an FDA-approved pharmaceutical drug. Its primary applications are as an indole derivative with antiviral and antitumor activity and as a building block for organic synthesis. No clinical trials or approved therapeutic indications exist.
|
| Molecular Formula |
C15H13NO
|
|---|---|
| Molecular Weight |
223.27
|
| Exact Mass |
223.099
|
| CAS # |
15903-94-3
|
| PubChem CID |
260804
|
| Appearance |
Off-white to light brown solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
411.6±20.0 °C at 760 mmHg
|
| Melting Point |
116-119°C
|
| Flash Point |
148.9±12.0 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.670
|
| LogP |
3.65
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
237
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)COC2=CC3=C(C=C2)C=CN3
|
| InChi Key |
FPMICYBCFBLGOZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C15H13NO/c1-2-4-12(5-3-1)11-17-14-7-6-13-8-9-16-15(13)10-14/h1-10,16H,11H2
|
| Chemical Name |
6-phenylmethoxy-1H-indole
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4789 mL | 22.3944 mL | 44.7888 mL | |
| 5 mM | 0.8958 mL | 4.4789 mL | 8.9578 mL | |
| 10 mM | 0.4479 mL | 2.2394 mL | 4.4789 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
